Plain-English translation of NCT07416240 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination treatment for advanced pancreatic cancer that uses two types of immune cells working together. The treatment combines activated dendritic cells (immune cells that help your body recognize cancer) with CAR-T cells (immune cells engineered to attack cancer). The goal is to help these cells work more effectively by breaking down the tumor's defenses and allowing the CAR-T cells to reach and destroy cancer cells more efficiently.
Advanced pancreatic cancer is very difficult to treat with standard chemotherapy alone, and many patients don't respond well to existing options. This trial exists because researchers believe that combining these two types of immune cells might be more powerful than treating with just one type, potentially offering hope to patients whose cancer hasn't responded to standard treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the combination treatment, which involves collecting your immune cells through a special blood collection process, activating them in the laboratory, and then infusing them back into your body. You would need to attend regular clinic visits for treatment administration, blood tests, and imaging scans to monitor how you respond. The trial will carefully track your health and any side effects throughout your participation.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China